ERNA has 36-month beta value of 4.50. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ERNA is 44.01M, and currently, short sellers hold a 12.47% ratio of that float. The average trading volume of ERNA on February 12, 2025 was 11.15M shares.
ERNA) stock’s latest price update
The stock of Eterna Therapeutics Inc (NASDAQ: ERNA) has decreased by -18.30 when compared to last closing price of 0.32.Despite this, the company has seen a loss of -26.47% in its stock price over the last five trading days. globenewswire.com reported 2025-01-09 that World-renowned researcher brings expertise in obstetrics and gynecology from Yale University to advance Eterna’s lead indication in ovarian cancer World-renowned researcher brings expertise in obstetrics and gynecology from Yale University to advance Eterna’s lead indication in ovarian cancer
ERNA’s Market Performance
Eterna Therapeutics Inc (ERNA) has experienced a -26.47% fall in stock performance for the past week, with a -12.03% drop in the past month, and a -75.56% drop in the past quarter. The volatility ratio for the week is 16.11%, and the volatility levels for the past 30 days are at 24.28% for ERNA. The simple moving average for the past 20 days is -36.99% for ERNA’s stock, with a -79.18% simple moving average for the past 200 days.
ERNA Trading at -25.89% from the 50-Day Moving Average
After a stumble in the market that brought ERNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.95% of loss for the given period.
Volatility was left at 24.28%, however, over the last 30 days, the volatility rate increased by 16.11%, as shares sank -14.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -43.62% lower at present.
During the last 5 trading sessions, ERNA fell by -26.69%, which changed the moving average for the period of 200-days by -84.83% in comparison to the 20-day moving average, which settled at $0.4189. In addition, Eterna Therapeutics Inc saw -10.24% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ERNA
Current profitability levels for the company are sitting at:
- -31.34 for the present operating margin
- -0.98 for the gross margin
The net margin for Eterna Therapeutics Inc stands at -75.14. The total capital return value is set at 8.39. Equity return is now at value -1154.18, with -149.86 for asset returns.
Based on Eterna Therapeutics Inc (ERNA), the company’s capital structure generated -2.83 points at debt to capital in total, while cash flow to debt ratio is standing at -0.51. The debt to equity ratio resting at -0.74. The interest coverage ratio of the stock is -5.12.
Currently, EBITDA for the company is -19.93 million with net debt to EBITDA at -0.75. When we switch over and look at the enterprise to sales, we see a ratio of 71.64. The receivables turnover for the company is 3.2for trailing twelve months and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.48.
Conclusion
To put it simply, Eterna Therapeutics Inc (ERNA) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
